{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:45:40Z","timestamp":1793418340444,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["23Y41900200"],"award-info":[{"award-number":["23Y41900200"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473166"],"award-info":[{"award-number":["82473166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972913"],"award-info":[{"award-number":["81972913"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002559"],"award-info":[{"award-number":["82002559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172712"],"award-info":[{"award-number":["82172712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970165"],"award-info":[{"award-number":["81970165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:45:10Z","timestamp":1773215110000},"page":"4001-4020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1\/2 clinical trial"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9532-4582","authenticated-orcid":false,"given":"Xiongfei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanshan","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suizhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gusheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6713-1185","authenticated-orcid":false,"given":"Gang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.012_bib1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.03.012_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1158\/2326-6066.CIR-15-0215","article-title":"Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens","volume":"4","author":"Prickett","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.03.012_bib4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib8","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","article-title":"Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results","volume":"30","author":"Parkhurst","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib9","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41467-019-08304-z","article-title":"Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients","volume":"10","author":"Cafri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.012_bib11","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.012_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s42003-024-06209-2","article-title":"Identification and affinity enhancement of T-cell receptor targeting a KRAS(G12V) cancer neoantigen","volume":"7","author":"Zhang","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161538","article-title":"Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors","volume":"14","author":"Ai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib14","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.012_bib15","article-title":"Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations","volume":"1","author":"Choi","year":"2021","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.ymthe.2026.03.012_bib16","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","article-title":"Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy","volume":"27","author":"Levin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175790","article-title":"Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors","volume":"134","author":"Bear","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.012_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.012_bib20","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib21","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.03.012_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib23","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib24","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/bjc.1995.66","article-title":"A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma","volume":"71","author":"Ravaud","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.012_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.03.012_bib27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181873","article-title":"Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A\u221711:01 pancreatic cancer patients","volume":"10","author":"Xu","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.03.012_bib29","article-title":"Advances in the management of pancreatic cancer","volume":"383","author":"Del Chiaro","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.03.012_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib31","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib32","doi-asserted-by":"crossref","first-page":"15685","DOI":"10.1074\/jbc.M210829200","article-title":"A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation","volume":"278","author":"Koike","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.03.012_bib33","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1021\/acs.jproteome.1c00239","article-title":"Ovalbumin Antigen-Specific Activation of Human T Cell Receptor Closely Resembles Soluble Antibody Stimulation as Revealed by BOOST Phosphotyrosine Proteomics","volume":"20","author":"Chua","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.03.012_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.012_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.ymthe.2026.03.012_bib37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1535-7163.MCT-21-0400","article-title":"Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19","volume":"21","author":"Tokunaga","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.03.012_bib39","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.012_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGF\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy","volume":"133","author":"Zanvit","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.012_bib41","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-24-3086","article-title":"IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation","volume":"31","author":"Wang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u2018Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib43","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"van Loenen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.03.012_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy","volume":"16","author":"Bendle","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.012_bib45","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/mt.2010.195","article-title":"Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.012_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.03.012_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.03.012_bib48","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-10-1280","article-title":"Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials","volume":"16","author":"Davis","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.012_bib49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/bjs\/znac457","article-title":"Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer","volume":"110","author":"Shi","year":"2023","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ymthe.2026.03.012_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000257","article-title":"Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"42","author":"Wang","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2026.03.012_bib51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2026.03.012_bib52","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.4049\/jimmunol.1000189","article-title":"Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase","volume":"184","author":"Frankel","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.012_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","article-title":"Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer cell"},{"key":"10.1016\/j.ymthe.2026.03.012_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ajh.26708","article-title":"Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"97","author":"Liu","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:25:23Z","timestamp":1793237123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525001626001978"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1\/2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}